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Background: It is clinically important to estimate the degree of endothelial dysfunction. Several methods
have been used to assess endothelial function in humans. Recently, we developed a new noninvasive
method for measurement of vascular response to reactive hyperemia in the brachial artery, named
enclosed zone ﬂow-mediated vasodilation (ezFMD). The purpose of this study was to determine the
validity of ezFMD for assessment of endothelial function.
Methods and results: We measured ezFMD by a new device using an oscillometric method and con-
ventional FMD using ultrasonography in 306 subjects, including patients with hypertension, dyslipide-
mia, and diabetes mellitus (218 men and 88 women, 30  16 yr). Univariate regression analysis revealed
that ezFMD signiﬁcantly correlated with age (r ¼ 0.42, P < 0.0001), body mass index (r ¼ 0.13,
P ¼ 0.028), systolic blood pressure (r ¼ 0.15, P ¼ 0.009), diastolic blood pressure (r ¼ 0.14, P ¼ 0.011),
fasting glucose level (r ¼ 0.27, P ¼ 0.006), smoking (r ¼ 0.21, P ¼ 0.007) and baseline pulse wave
amplitude (r ¼ 0.51, P < 0.0001). ezFMD signiﬁcantly correlated with conventional FMD (r ¼ 0.34,
P < 0.0001). Multiple regression analysis revealed that age (P ¼ 0.002), body mass index (P ¼ 0.013),
systolic blood pressure (P ¼ 0.009), smoking (P ¼ 0.004) and baseline pulse wave amplitude (P < 0.001)
were independent predictors of ezFMD.
Conclusions: These ﬁndings suggest that measurement of ezFMD, a novel noninvasive and simple
method, may be useful for determination of vascular diameter response to reactive hyperemia. Since
ezFMD is automatically measured by a device with an oscillometric method, measurement of ezFMD is
easier and less biased than that of conventional FMD.
 2013 Elsevier Ireland Ltd. Open access under CC BY-NC-ND license.ion and Medicine, Research
tute for Radiation Biology and
ami-ku, Hiroshima 734-8551,
gashi).
er CC BY-NC-ND license.1. Introduction
Endothelial dysfunction is an early feature of atherosclerosis and
vascular diseases in humans [1]. It is clinically important to esti-
mate the degree of endothelial dysfunction. Several methods have
been used to assess endothelial function in humans [2e19].
Recently, several investigators, including us, have evaluated the
effects of intra-arterial infusion of nitric oxide (NO) agonists, such
as acetylcholine, methacholine, and bradykinin, and the effects of
N. Idei et al. / Atherosclerosis 229 (2013) 324e330 325intra-arterial infusion of NO antagonists on forearm blood ﬂow
using a mercury-ﬁlled silastic strain-gauge plethysmography and
the effects on coronary blood ﬂow using a Doppler ﬂow guide wire
[2e14]. Responses to intra-arterial infusion of vasoactive agents
should be considered as the gold standard for assessing endothelial
function, because the use of agonists to stimulate NO release and
the use of antagonists of NO allow us to draw more speciﬁc con-
clusions concerning the role of basal and stimulated NO release.
However, the invasive methods are time-consuming and are a
burden for patients. Measurement of ﬂow-mediated vasodilation
(FMD) in the brachial artery using ultrasound is noninvasive and is
an accurate indicator of NO production [15e19]. However, evalua-
tion by FMD measurement requires skill in measurement of the
vessel diameter by an ultrasound system, and the FMD measure-
ment system is difﬁcult to handle. Moreover, the technique requires
a large-scale apparatus.
Blood pressure can be easily and noninvasively measured by
an automatic device using an oscillometric method. When
measuring blood pressure by an automatic device, oscillation
amplitude can be measured at the same time. We hypothesized
that change in oscillation amplitude caused by ischemia could
reﬂect FMD, since change in oscillation amplitude caused by
ischemia is proportional to vessel volumetric change. In other
words, conventional FMD is measured by change in vascular
diameter, whereas ezFMD is measured by change in vascular
volume. In accordance with this theory, we recently developed a
new noninvasive and simple method for measurement of vascular
response to reactive hyperemia in the brachial artery, named
enclosed zone FMD (ezFMD).
In this study, we evaluated the usefulness of ezFMD for assess-
ment of endothelial function and compared the results obtained by
ezFMD and conventional FMD.2. Methods
2.1. Subjects
We studied 306 subjects, including hypertension, dyslipidemia,
and diabetes mellitus (218 men and 88 women, 30  16 yr). Hy-
pertension was deﬁned as systolic blood pressure of more than
140 mm Hg and/or diastolic blood pressure of more than 90 mm
Hg, in a sitting position, on at least three different occasions. Pa-
tients with secondary forms of hypertension were excluded on the
basis of complete history, physical examination, radiological and
ultrasound examinations, urinalysis, plasma renin activity, plasma
aldosterone and norepinephrine concentrations, serum creatinine,
potassium, calcium, and free thyroxine concentrations, and 24-
h urinary excretion of 17-hydroxycorticosteroids, 17-ketogenic
steroids, and vanillymandelic acid. Normotension was deﬁned as
systolic blood pressure of less than 140 mm Hg and diastolic blood
pressure of less than 90 mm Hg. Diabetes was deﬁned according to
the American Diabetes Association [20] and/or a previous diag-
nosis of diabetes. Dyslipidemia was deﬁned according to the third
report of the National Cholesterol Education Program [21]. Current
smokers were deﬁned as any who had smoked at least 1 pack-
year. One pack-year was deﬁned as 20 cigarettes per day for 1
year. All of the smokers (18.5  8.7 pack-years) had a current
smoking history of more than 5 years and abstained from smoking
for at least 3 h before the measurement of vascular function. We
deﬁned nonsmokers as those who had never smoked. The study
protocol was approved by the Ethical Committee of Hiroshima
University Graduate School of Biomedical Sciences. Informed
consent for participation in the study was obtained from all
subjects.2.2. Study protocol
All studies were performed in the morning, after overnight
fasting, in a quiet, dark, air-conditioned room (constant tempera-
ture of 22e25 C). Measurements of ezFMD and FMD were
randomly performed on separate day. None of the subjects were
taking oral antioxidant vitamins or vasoactive drugs, including
antihypertensive agents, antidiabetic agents and statins before the
study.
Subjects fasted the previous night for at least 12 h. Thirty mi-
nutes after remaining in the supine position, fasting serum con-
centrations of total cholesterol, high-density lipoprotein (HDL)
cholesterol, low-density lipoprotein (LDL) cholesterol, triglycerides,
and glucose were measured.
2.3. Measurement of ezFMD
Oscillometric noninvasive blood pressure measurement is
widely performed in a clinical setting. The theory is that the arterial
wall contains zero stress and the vessel is minimally distended
when external or cuff pressure is equal to arterial pressure [22,23].
Cuff wave pressure is a signal of variation of internal cuff pressure
and arises from volumetric change in the cuff, which, in turn,
originates from volumetric pulse change in the artery. When arte-
rial vessel volume increases, cuff volume decreases and cuff inter-
nal pressure increases. Repetition of changes in arterial vessel
volume and cuff volume shows the oscillation signal. The magni-
tude of oscillation and volumetric change in the artery shows a
close proportional relation. Cuff pressure associated with the
largest oscillation amplitude can be considered as mean blood
pressure. Supplemental Fig. S1A shows the relationship between
cuff pressure and oscillation amplitude. A pressure at the largest
oscillation during the deﬂation period as mean blood pressure and
determines systolic blood pressure and diastolic blood pressure at
50% of the largest one are obtained (Supplemental Fig. S1B). The
vascular response to reactive hyperemia in the brachial artery was
assessed for oscillation amplitude measurement of ezFMD. We
assessed pulse wave with an OPV 1500 (Nihon Koden. Co., Tokyo,
Japan) (Supplemental Fig. S2). Oscillometry is a commonly used
noninvasive method for measuring blood pressure with a sphyg-
momanometer cuff tied around the upper arm. After the cuff is
inﬂated to a level higher than systolic blood pressure, it is deﬂated
slowly, and blood pressure is estimated on the basis of oscillation
signals recorded from the internal cuff pressure. At ﬁrst, we
measured blood pressure ﬁve times on the proximal forearm in the
seated position at rest with this device, and after interrupting blood
ﬂow for 5 minwith the cuff, we measured blood pressure for 5 min
consecutively automatically. We adopted each maximal oscillation.
The cuff was inﬂated up to systolic pressure plus 50 mmHg. For
every cuff pressure deﬂation of 5 mmHg, two oscillation signal
pulses were detected. In each step, detection of two oscillation
signal pulses and deﬂation of the cuff were repeated, and cuff
pressure was released at the point when diastolic pressure was
reached. The average of the oscillation amplitude of two pulses was
considered as the typical value of the oscillation amplitude at each
cuff pressure step. We used the maximum typical value of one
measurement sequence to calculate the compliance change. ezFMD
was calculated by the following equation: %ezFMD ¼ [(peak oscil-
lation amplitudebaseline oscillation amplitude)/baseline oscilla-
tion amplitude] 100 (Fig. 1, A and B). In the after-occlusion period,
the average of the third to ﬁfth of 5 measurements was used for
analysis of peak oscillation amplitude. Two observers who were
blind to the form of examination performed themeasurements. The
coefﬁcients of variation of intra- and inter-observer ezFMD mea-
surements were 3.8% and 5.9%, respectively.
Fig. 1. (A) Representative data on oscillation amplitude at baseline, during cuff occlusion, and after cuff release. (B) Changes in enclosed zone ﬂow-mediated vasodilation (ezFMD).
Baseline 1e5 indicates order number of baseline oscillometric measurement, and After 1e8 indicates order number of oscillometric measurement after cuff release.
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FMD was assessed using an ultrasonograph (UNEXEF18G, UNEX
Co., Nagoya, Japan) as previously described [24,25]. Please see the
online data supplement for additional details.
2.5. Theoretical relationship between ezFMD and FMD
We hypothesized the theoretical correlation between ezFMD
and FMD. Please see the online data supplement for additional
details.
2.6. Statistical analysis
Results are presented as means  SD. All reported P values were
2-sided, and a P value of <0.05 was considered statistically signif-
icant. Unpaired Student’s t test was used for comparison of mean
values of parametric continuous variables between the two groups.
Categorical variables were compared by the chi-square test. Re-
lations between variables were determined by liner regression
analysis. Relation between ezFMD and FMD was assessed using
Pearson’s correlation coefﬁcients analysis. Multivariate regression
analyses were performed to identify independent factorsassociated with ezFMD in risk factors and laboratory data. The
receiver operating characteristic (ROC) curve analyses was carried
out to assess the sensitivity and speciﬁcity of measurements of
ezFMD and FMD for diagnosing cardiovascular diseases. The data
were processed using the software package Stata version 9 (Stata
Co., College Station, Texas, USA).
3. Results
3.1. Clinical characteristics
Baseline clinical characteristics in subjects are summarized in
Table 1.
3.2. ezFMD
Table 2 shows vascular functions in all subjects.
ezFMD was signiﬁcantly lower in patients with cardiovascular
diseases (CVDs) (n ¼ 72, 49 men, 58  12 yr) than in age- and
gender-matched healthy subjects (n ¼ 72, 49 men, 57  14 yr)
(25.8  18.4% vs. 43.2  18.6%, P < 0.0001) (Fig. 2). There was no
signiﬁcant difference between baseline oscillation amplitudes in
the two groups.
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Fig. 2. Changes in enclosed zone ﬂow-mediated vasodilation (ezFMD) in healthy
subjects and patients with cardiovascular diseases (CVDs). Baseline 1e5 indicates order
number of baseline oscillometric measurement, and After 1e8 indicates order number
of oscillometric measurement after cuff release.
Table 3a
Univariate analysis of the relationship between enclosed zone ﬂow-mediated
vasodilation and variables.
Variables r 95% CI P value
Age, years 0.415 0.633 0.381 <0.0001
Body mass index, kg/m2 0.130 1.904 0.109 0.0281
Table 1
Clinical characteristics of subjects.
Variables n ¼ 306
Age, yr 30  16
Body mass index, kg/m2 21.6  2.7
Systolic blood pressure, mm Hg 115.7  14.9
Diastolic blood pressure, mm Hg 64.3  11.2
Heart rate, bpm 68.2  12.6
Total cholesterol, mmol/L 4.86  0.95
Triglycerides, mmol/L 1.50  1.05
High-density lipoprotein cholesterol, mmol/L 1.46  0.56
Low-density lipoprotein cholesterol, mmol/L 2.86  0.85
Glucose, mmol/L 5.9  1.5
HbA1c, % 5.2  0.7
Hypertension, n (%) 46 (15)
Dyslipidemia, n (%) 36 (12)
Diabetes mellitus, n (%) 9 (3)
Smokers, n (%) 53 (17)
All results are presented as mean  SD.
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correlated with age (r ¼ 0.42, P < 0.0001), body mass index
(r ¼ 0.13, P ¼ 0.0281), systolic blood pressure (r ¼ 0.15,
P¼ 0.0099), diastolic blood pressure (r¼0.14, P¼ 0.0108), fasting
glucose level (r¼0.27, P¼0.0056), smoking (r¼0.21, P¼0.0071)
and baseline oscillation amplitude (r¼0.51, P< 0.0001) (Tables 3a
and b). ezFMD signiﬁcantly correlated with conventional FMD
(r ¼ 0.34, P < 0.0001) (Fig. 3). Multiple regression analysis revealed
that age, body mass index, systolic blood pressure, smoking, and
baseline oscillation amplitude were independent predictors of
ezFMD (Tables 3a and b).
3.3. FMD
FMD was signiﬁcantly lower in patients with CVD (n ¼ 72, 49
men, 58 12 yr) than in age- and gender-matched healthy subjects
(n ¼ 72, 49 men, 57  14 yr) (4.5  2.1% vs. 6.9  2.7%, P ¼ 0.0012).
There was no signiﬁcant difference between the two groups base-
line brachial artery diameter and reactive hyperemic ﬂow.
Univariate regression analysis revealed that FMD signiﬁcantly
correlated with age (r ¼ 0.28, P ¼ 0.0005), body mass index
(r ¼ 0.17, P ¼ 0.0090), systolic blood pressure (r ¼ 0.13,
P ¼ 0.0398), fasting glucose level (r ¼ 0.37, P ¼ 0.0002), smoking
(r ¼ 0.17, P ¼ 0.0077) and baseline brachial artery diameter
(r ¼ 0.42, P < 0.0001) (Tables 4a and b). Multiple regression
analysis revealed that age, systolic blood pressure, and baseline
brachial artery diameter were independent predictors of FMD
(Tables 4a and b).
3.4. Diagnostic accuracy of ezFMD and FMD
The ROC curves of ezFMD and FMD for diagnosing CVD history
are shown in Fig. 4. The area under the curve values of ROC curves
for ezFMD and FMD to diagnose CVD were 0.705 and 0.673
(P < 0.0001), respectively.Table 2
Vascular function.
Enclosed zone ﬂow-mediated vasodilation
Baseline oscillation amplitude, mm Hg 1.5  0.5
Enclosed zone ﬂow-mediated vasodilation, % 30.4  18.5
Flow-mediated vasodilation
Baseline brachial artery diameter, mm 3.7  0.5
Increase in hyperemic ﬂow, % 381  198
Flow-mediated vasodilation, % 6.7  2.34. Discussion
We developed a new device for fully automatic measurement of
endothelial function using an oscillometric method, named ezFMD.
Conventional measurement of FMD using ultrasonography is
measured by change in vascular diameter, whereas ezFMD is
measured by change in vascular volume. Although both ezFMD and
FMD are equally useful for assessing endothelial function, mea-
surement of ezFMD is easier and less biased than measurement of
FMD.
It is accepted that measurement of forearm blood ﬂow re-
sponses to vasoactive agents by plethysmography is an index of
resistance artery endothelial function and that measurement of
FMD is an index of conduit artery endothelial function, suggesting
that plethysmography and FMDmeasurement do not assess similar
endothelial function. The measurement principle of ezFMD is
similar to that of FMD. Thus, we comparedmeasurements of ezFMD
and FMD.Systolic blood pressure, mm Hg 0.149 0.349 0.050 0.0099
Diastolic blood pressure, mm Hg 0.144 0.454 0.061 0.0108
Heart rate, bpm 0.094 0.082 0.164 0.6785
Total cholesterol, mmol/L 0.030 0.137 0.104 0.7877
Triglycerides, mmol/L 0.098 0.076 0.017 0.2123
High-density lipoprotein cholesterol,
mmol/L
0.110 0.132 0.278 0.1815
Low-density lipoprotein cholesterol,
mmol/L
0.012 0.141 0.126 0.9136
Glucose, mmol/L 0.274 0.441 0.130 0.0056
Smoking, pack year 0.209 0.477 0.144 0.0071
Baseline oscillation amplitude, mm Hg 0.512 0.066 0.045 <0.0001
Table 3b
Multivariate analysis of the relationship between enclosed zone ﬂow-mediated
vasodilation and variables
Variables b t value P value
Age, years 0.492 2.886 0.0018
Body mass index, kg/m2 0.298 2.298 0.0132
Systolic blood pressure, mm Hg 0.317 2.824 0.0091
Diastolic blood pressure, mm Hg 0.023 0.190 0.7801
Glucose, mmol/L 0.238 1.238 0.2230
Smoking, pack year 0.414 3.457 0.0038
Baseline oscillation amplitude, mm Hg 0.513 4.039 0.0003
Table 4a
Univariate analysis of the relationship between ﬂow-mediated vasodilation and
variables.
Variables r 95% CI P value
Age, years 0.281 0.112 0.045 0.0005
Body mass index, kg/m2 0.171 0.420 0.056 0.0090
Systolic blood pressure, mm Hg 0.127 0.059 0.005 0.0398
Diastolic blood pressure, mm Hg 0.122 0.054 0.002 0.0472
Heart rate, bpm 0.064 0.017 0.051 0.3167
Total cholesterol, mmol/L 0.104 0.026 0.009 0.0833
Triglycerides, mmol/L 0.044 0.026 0.019 0.7511
High-density lipoprotein cholesterol,
mmol/L
0.108 0.038 0.055 0.0721
Low-density lipoprotein cholesterol,
mmol/L
0.110 0.026 0.019 0.0698
Glucose, mmol/L 0.368 0.029 0.016 0.0002
Smoking, pack year 0.173 0.114 0.018 0.0077
Baseline brachial artery diameter, mm 0.416 3.193 1.813 <0.0001
N. Idei et al. / Atherosclerosis 229 (2013) 324e330328In the present study, we conﬁrmed that ezFMD correlated with
conventional cardiovascular risk factors, including age, body mass
index, blood pressures, glucose, and smoking. Age, systolic blood
pressure, smoking, and baseline oscillation amplitude were inde-
pendent predictors of ezFMD. ezFMD was signiﬁcantly lower in
patients with CVDs than in healthy subjects. Although there was no
signiﬁcant difference in the ROC curves for diagnosing CVD history
between ezFMD and FMD, the value of ezFMD tended to be high
compared with that of FMD. These ﬁndings suggest that mea-
surements of ezFMD as well as FMD are useful for assessing
endothelial function. Several lines of evidence have shown that
assessment of endothelial function, including vascular responses to
vasoactive agents and FMD, can serve as an independent predictor
of cardiovascular events. It is expected that ezFMDwill also become
a surrogate marker for the grade of atherosclerosis and cardiovas-
cular outcomes.
Measurement of ezFMD has a number of advantages as follows.
Since only measurement of the amplitude of oscillation is required,
the analyzing unit does not need to have a high processing capacity.
When measuring conventional FMD by an ultrasound system, the
observer has to set a transducer to image the brachial artery and
has to measure the changes in brachial artery diameter manually or
using tracking software. A high level of technical skills is required to
use an ultrasound system, especially when using a transducer, as
described in the guidelines for FMD measurement [26e28]. In
addition, an ultrasound system is very expensive. When measuring
ezFMD, all that is required is to place a cuff on the arm as for
measurement of blood pressure. Therefore, artiﬁcial bias, including
manipulation of the transducer and operation of the ultrasound
system, can be avoided by measurement of ezFMD. Consequently,
the present invention is advantageous in operation.-20
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Fig. 3. Relationship between enclosed zone ﬂow-mediated vasodilation (ezFMD) and
conventional FMD.Change in vascular volume after pressure stimulation is
measured, and information equivalent to that obtained by the
reliable FMD method can thus be easily obtained, and the mea-
surement can be performed by a technique and conﬁguration that
are similar to those for blood pressure measurement. Therefore,
technical skills for measurement are not required. The vessel
volumetric change obtained in the present invention is the change
of vascular volume in the area where the cuff is attached. The cuff-
attached area is constant in a series of measurements, and hence
the vessel volumetric change can be deemed as a change in vessel
sectional area. While change in vessel diameter is obtained by the
FMD method, the square of the vessel diameter can be deemed as
the sectional area. An idle period when the cuff pressurization is
stopped exists between the pressure stimulation and the oscillation
amplitude measurement. Therefore, a continuous vessel blocking
period is minimized and the burden for the subject is therefore
reduced.
In the present study, there was a weak association between
ezFMD and FMD and there were relative strong correlations of
ezFMDwith age, SBP and baseline arterial diameter, suggesting that
ezFMD is more strongly related to arterial stiffness and/or blood
pressure than to FMD. These ﬁndings suggest that ezFMD is more
effective than FMD for conﬁrming the atherosclerosis and indicate
the possibility that ezFMD is superior to FMD. In other words,
ezFMD may be a new marker including both indices of endothelial
function and arterial stiffness. Measurements of arterial stiffness
parameters would be helpful to conﬁrm the concept that ezFMD
includes components of both endothelial function and arterial
stiffness.
4.1. Study limitations
We hypothesized a theoretical correlation in which the value of
ezFMD is approximately two-times higher than that of FMD.Table 4b
Multivariate analysis of the relationship between ﬂow-mediated vasodilation and
variables
Variables b t value P value
Age, years 0.374 3.361 0.0063
Body mass index, kg/m2 0.089 0.812 0.2855
Systolic blood pressure, mm Hg 0.353 3.121 0.0074
Diastolic blood pressure, mm Hg 0.035 0.221 0.7259
Glucose, mmol/L 0.156 0.705 0.4847
Smoking, pack year 0.038 0.681 0.5012
Baseline brachial artery diameter, mm 0.538 5.125 0.0001
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mately four-times higher than that of FMD. Guidelines for man-
agement of FMD recommend the forearm occlusion method [26e
28]. Unfortunately, when the occlusion cuff was placed on the
forearm, signals of oscillation after cuff release were not completely
obtained. Therefore, we selected the upper arm cuff occlusion
method to measure ezFMD. FMD in the brachial artery was
measured using a forearm occlusion method, as previously
described [15e19,24,25]. The positions where the cuff is placed
should contribute to different values of vasodilatory response to
reactive hyperemic ﬂow through various factors, especially differ-
ence in forces of shear stress. It is well known that NO production
from endothelial cells increases in relation to the degree of shear
stress. In a preliminary study, we conﬁrmed that the value of FMD
obtained by using upper arm occlusion was approximately two-
times higher than that of FMD using forearm occlusion in 50
healthy men (29.3 2.3 yr, 13.9 1.9% vs. 6.7 1.4%, P¼ 0.001) and
in 39 patients with CVDs (29 men and 10 women, 63.1  7.2 yr,
8.7  1.6% vs. 4.1 1.2%, P ¼ 0.002). Our results are consistent with
results of previous studies showing that FMD in the brachial artery
after upper arm occlusion was approximately two-times higher
than FMD after forearm occlusion [19]. Since upper arm occlusion is
used, the ezFMD measures will not directly be a reﬂection of
endothelial function e rather they will be a reﬂection of a combi-
nation of NO and prostaglandin metabolite release. Forearm oc-
clusion for measurement of FMD has a number of advantages. In
particular, vasodilation of the brachial artery after release of the cuff
placed on forearm reﬂects NO release more than does vasodilation
induced by upper arm occlusion [19]. In the future, it is expected
that a device using forearm occlusion for measurement of ezFMD
will be developed.
Measurement of ezFMD is based on the following two as-
sumptions: 1) when the degree of vasodilation increases, pulsation
of the brachial artery cross-sectional area increases and 2) when
the brachial artery cross-sectional area increases, oscillation
amplitude increases. We believe that the theoretical concept con-
cerning measurement of ezFMD is correct since the two assump-
tions for measurement of ezFMD were conﬁrmed using a
simulation model in a preliminary study.In conclusion, we demonstrated for theﬁrst time the feasibility of
a new method that can automatically assess endothelial function,
namedezFMD.Conventional FMD ismeasuredbychanges inbrachial
artery diameter, whereas ezFMD is measured by changes in vessel
volume in the brachial artery. In addition, ezFMD is automatically
measured using a device with an oscillometric method. Therefore,
we emphasize that measurement of ezFMD is easier and less biased
than conventional FMDmeasurement. Further studies are needed to
determinewhether ezFMD is a predictor of cardiovascular outcomes
ina large clinical trial. In addition,weshould compare theROCcurves
of ezFMD and FMD for diagnosing CVD outcomes.
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